View Financial HealthAbpro Holdings 배당 및 자사주 매입배당 기준 점검 0/6Abpro Holdings 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률-782.6%자사주 매입 수익률총 주주 수익률-782.6%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • May 16Abpro Holdings, Inc. announced delayed 10-Q filingOn 05/15/2026, Abpro Holdings, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Apr 01Abpro Holdings, Inc. announced delayed annual 10-K filingOn 03/31/2026, Abpro Holdings, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.공시 • Feb 21Abpro Holdings, Inc. Receives Notice of Nasdaq Delisting and Trading Suspension on February 23, 2026On February 18, 2026, Abpro Holdings, Inc. (the Company") received written notification from the Nasdaq Hearings Panel (the Panel") of the Nasdaq Stock Market LLC (Nasdaq") stating that, due to the Company not having met the terms of the Panel's November 10, 2025 decision that the Company demonstrate compliance with the minimum equity standard requirement under Nasdaq Listing Rule 5550(b)(1) by February 16, 2026, the Company's securities will be delisted from Nasdaq, and trading will be suspended at the open of trading on February 23, 2026. The Company has 15 days after the date it received notice of the Panel's decision to request that the Nasdaq Listing and Hearing Review Council (the Council") review the decision. The Company expects to appeal the Panel's decision. If no appeal is taken, the Company expects Nasdaq will file a Form 25 with the SEC to delist the securities from Nasdaq and deregister the securities under Section 12(b) of the Securities Exchange Act of 1934, as amended. Following suspension of trading on Nasdaq, the Company expects its common stock will be eligible for quotation on the OTC Pink Market under its existing symbol, ABP" and its public warrants under the existing symbol ABPWW." The Company can provide no assurances that any broker-dealer will make a market in its common stock or public warrants or that trading levels, liquidity, or quotation prices will be maintained. The Company also cautions its stockholders and public warrant holders that trading on the OTC Pink Market may be subject to limited availability of information, reduced transparency and liquidity and greater volatility.공시 • Feb 12Abpro Holdings, Inc. Receives Non-Compliance Notice from NasdaqAs previously disclosed, on January 28, 2026, Anthony D. Eisenberg notified the Board of Directors (the Board") of Abpro Holdings, Inc. (the Company") of his resignation from the Board and all committees thereof. On January 30, 2026, Sooyoung Lee notified the Board of his resignation from the Board and all committees thereof. Following these resignations, the Board has initiated a process to identify and appoint qualified independent directors to fill the resulting vacancies and to satisfy the applicable requirements of The Nasdaq Stock Market (Nasdaq"). On February 5, 2026, the Company received written notice from Nasdaq stating that, as a result of the resignations described above, the Company is no longer in compliance with Nasdaq Listing Rule 5605(b)(1), which requires a majority of the Board to be comprised of independent directors as defined in Nasdaq Listing Rule 5605(a)(2), and Nasdaq Listing Rule 5605(c)(2), which requires the audit committee of the Board (the Audit Committee") to consist of at least three members, each of whom is an independent director under the Nasdaq Listing Rules and meets the heightened independence standards applicable to audit committee members. Furthermore, the Company is not eligible for the cure period provided under Nasdaq Listing Rules 5605(b)(1)(A) and 5605(c)(4) because there is more than one vacancy on the Board and the Audit Committee. Accordingly, the Company's noncompliance with Nasdaq Listing Rules 5605(b)(1)(A) and 5605(c)(4) constitutes additional bases for delisting the Company's securities from Nasdaq. The notice further stated that the Nasdaq Hearings Panel (the Panel") will consider these additional deficiencies in connection with its determination regarding the Company's continued listing on The Nasdaq Capital Market and required the Company to submit its views with respect to these matters to the Panel in writing no later than February 12, 2026. On February 5, 2026, the Company received a separate notice from Nasdaq notifying the Company that as a result of the resignations of Mr. Eisenberg and Mr. Lee, the Company no longer complies with Nasdaq's compensation committee requirements as set in Nasdaq Listing Rule 5605(d)(2)(A), which requires the Company's compensation committee (the Compensation Committee") to consists of at least two members, each of whom is an independent director under the Nasdaq Listing Rules. The notice provides that consistent with Nasdaq Listing Rule 5605(d)(4), the Company has a cure period to regain compliance, which extends until (1) the earlier of the Company's next annual shareholders' meeting or January 30, 2027; or (2) if the next annual shareholders' meeting is held before July 29, 2026, then the Company must evidence compliance no later than July 29, 2026. The Company intends to appoint qualified replacements to fill the vacancies on its Compensation Committee who satisfy the applicable requirements of the Nasdaq Listing Rules prior to the expiration of the applicable cure period. Neither of the Nasdaq notices has an immediate effect on the listing of the Company's common stock or warrants on Nasdaq. However, there can be no assurance that the Panel will grant the Company's request for continued listing or that the Company will be able to regain compliance with the applicable Nasdaq Listing Rules within the required time periods.공시 • Jan 24Abpro Holdings, Inc. Announces Board and Committee ChangesAbpro Holdings, Inc. announced that on January 16, 2026, Ian McDonald, a member of the Board of Directors (the “Board”) of the Company, notified the Board that he was resigning from the Board, including all committees of the Board. Mr. McDonald did not resign due to any disagreement with the Company, its board of directors or its management regarding any matters relating to the Company’s operations, policies or practices. On January 16, 2026, the Board appointed Dr. Byung-Hak Yoon to fill the vacancy resulting from Mr. McDonald’s resignation. Dr. Yoon will serve as a Class I director with a term ending at the 2028 annual meeting and will fill the vacancies on the Company’s Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee resulting from Mr. McDonald’s resignation. Dr. Yoon, age 51, currently serves as CEO of OQPBIOM, a biotechnology company (since March 2025), and CEO of Doowon Science Pharma (since October 2023). From June 2020 to March 2025, he served as President of CanariaBio Group. From 2022 to 2025, he served as CEO of Sejong Medica, a medical device company. From January 2020 to January 2023, he served as Chairman and CEO of Thelma Therapeutics, and from September 2018 to January 2020, he served as CEO of AXCESO Biopharma. Since January 2018, he has served as a member of the Government Project Review Committee, Ministry of SMEs and Startups, Korea, and as a member of the Government Project Review Committee, Korea Health Industry Development Institute, Korea, since February 2013. Dr. Yoon was appointed to the Board because of his extensive experience in the pharmaceutical industry.공시 • Jan 07Abpro Holdings, Inc. and Celltrion, Inc. Announce U.S. FDA IND Clearance for Lead Multispecific Antibody Cancer Candidate ABP-102 / CT-P72Abpro Holdings, Inc. announced, together with its co-development partner Celltrion, Inc., that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for ABP-102 /CT-P72, Abpro's lead multispecific antibody oncology program. The IND clearance enables the initiation of a Phase 1 clinical trial evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of ABP-102 /CT-P72 in patients with HER2-positive solid tumors. The Phase 1 clinical study will be led by Celltrion as part of the ongoing joint strategic collaboration to ensure the robust progression of the ABP-102 /CT -P72 program. ABP-102 /CT the company is a multispecific HER2 x CD3 T-cell engager engineered to selectively target HER2-overexpressing tumor cells while engaging cytotoxic T cells, with optimized binding designed to enhance tumor selectivity and limit activity in normal HER2-low tissues. This design is intended to direct immune activity toward cancer cells while seeking to minimize damage to healthy tissue, addressing a key safety challenge that has limited the use of T-cell engagers in solid tumors. In preclinical studies, ABP-102 /CT/CT-P72 demonstrated robust antitumor activity in HER2-high tumor models, including dual xenograft models containing both HER2-high and HER2-low tumors, with selective efficacy for HER2-high tumors. The optimized CD3 binding of ABP-102/CT-P72, functionally linked with HER2-high selectivity, is intended to mitigate excessive immune activation and reduce the risk of cytokine release syndrome. Non-human primate toxicology studies showed the candidate was well tolerated at doses up to 80 mg/kg, with no significant adverse effects observed, supporting a differentiated therapeutic index. Additional preclinical evaluations demonstrated activity in tumor models representing resistance to existing HER2-directed therapies, highlighting the potential to address areas of unmet medical need. Preclinical data sets for ABP-102 /TC-P72 have been presented at major scientific meetings, including the 2025 Annual Meeting of the American Association for Cancer Research and the 2025 Annual Meeting of the Society for Immunotherapy of Cancer. Following IND clearance, Abpro and Celltrion plan to initiate a global Phase 1 clinical trial in the first half of 2026, subject to final site activation and regulatory processes. The study is expected to include dose-escalation and dose-expansion cohorts and will inform future clinical development strategies.공시 • Dec 16Abpro Holdings, Inc. and Celltrion, Inc. Announces Submission of an IND Application to Initiate a Phase 1 Clinical Trial of T Cell Engager ABP-102/CT-P72 for HER2-Positive CancersAbpro Holdings, Inc. together with its co-development partner Celltrion, Inc. announced the submission of an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for ABP-102/CT-P72, a HER2 x CD3 T cell engager engineered with optimized CD3 and HER2 binding to improve tumor selectivity. Pending regulatory clearance, this IND will support the initiation of a phase 1 clinical trial, anticipated to begin in 1H 2026 in patients with HER2-positive cancers including breast and gastric cancers. This submission represents a significant milestone in the companies' collaborative development of ABP- 102/CT-P72 and marks an important advance for Abpro's broader immuno-oncology pipeline. Upon FDA authorization to proceed, the planned phase 1 study will evaluate the safety, pharmacokinetics, and preliminary efficacy of ABP-102/CT-P72 in a dose-escalation and dose-expansion format. Data generated from the trial will inform dose selection and guide subsequent clinical development.공시 • Oct 18Nasdaq Schedules Hearing for Abpro Holdings, Inc. Regarding Delisting NoticeAs previously disclosed, Abpro Holdings, Inc. (the Company") requested a hearing (the Hearing") before an independent Hearings Panel (the Panel") regarding a delisting notice in connection with its failure to comply with Nasdaq Listing Rule 5450(a)(1) (the Minimum Bid Price Requirement"). The Hearing has been scheduled for October 30, 2025. As previously disclosed, on April 10, 2025, the Company received two letters from the listing qualifications department staff of The Nasdaq Stock Market (Nasdaq"). One letter (the MVPHS Notice") indicated that based upon Nasdaq's review of the Company's Market Value of Publicly Held Shares (MVPHS") for the last 30 consecutive business days prior to the date of the MVPHS Notice, the Company no longer meets the requirements of Nasdaq Listing Rule 5450(b)(2)(C), which requires listed securities to maintain a minimum MVPHS of $15,000,000 (theMVPHS Requirement"). The second letter notified the Company that from February 20, 2025, to April 9, 2025, the Company's Market Value of Listed Securities (MVLS") was below the minimum of $50 million required for continued listing on The Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(b)(2)(A) (the MVLS Requirement"). Each letter stated that the Company had 180 calendar days, or until October 7, 2025, to regain compliance. On October 14, 2025, the Company received a letter (the Notice") from Nasdaq notifying the Company that it had not regained compliance with either the MVPHS Requirement or the MVLS Requirement during the compliance period. During the Hearing, the Company will present its plans to regain compliance with the Minimum Bid Price Requirement, the MVPHS requirement and the MVLS requirement. Any further delisting action has been stayed pending the Panel's decision and/or any further extension provided by the Panel; therefore, the Notice has no immediate effect on the listing of the Company's common stock or warrants on Nasdaq. There can be no assurance that the Panel will grant the Company's request for continued listing or that the Company will be able to evidence compliance prior to the expiration of any extension that may be granted by the Panel.공시 • Oct 04Abpro Holdings Receives Notice of Nasdaq Delisting Due to Non-Compliance with Bid Price RuleAs previously reported, on April 2, 2025, Abpro Holdings, Inc. received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that it no longer complied with the minimum bid price requirement for continued listing on Nasdaq. Nasdaq Listing Rule 5450(a)(1) requires listed securities to maintain a minimum bid price of $1.00 per share. The letter stated that the Company had 180 calendar days, or until September 29, 2025, to regain compliance. On September 30, 2025, the Company received a letter from Nasdaq notifying the Company that it had not regained compliance with the Minimum Bid Price Requirement during the compliance period. Accordingly, unless the Company requests an appeal by October 7, 2025, the Company’s common stock will be scheduled for delisting at the opening of business on October 9, 2025. Accordingly, the Company intends to timely request a hearing before the appeal panel. The hearing request will stay the suspension of the Company’s securities with Nasdaq pending the Panel’s decision or any extension of time provided by the Panel to regain compliance. During the hearing, the Company will present its plans to regain compliance with the bid price and all other continued listing requirements. There can be no assurance that the Panel will grant the Company’s request for continued listing or that the Company will be able to evidence compliance prior to the expiration of any extension that may be granted by the Panel.공시 • May 01Abpro Holdings, Inc., Annual General Meeting, May 20, 2025Abpro Holdings, Inc., Annual General Meeting, May 20, 2025.공시 • Apr 28Abpro and Celltrion Unveil Preclinical Data for ABP-102/CT-P72 at AACR 2025, Showcasing Potential Best-in-Class HER2 x CD3 T-Cell EngagerAbpro Holdings, Inc. and Celltrion unveiled preclinical data for ABP-102/CT-P72 in an oral presentation at the American Association for Cancer Research® (AACR) Annual Meeting 2025, in the New Drugs on the Horizon session. ABP-102/CT-P72, a tetravalent bispecific HER2 x CD3 T-cell engager co-developed with Celltrion, is engineered to selectively target HER2-overexpressing tumors while reducing the risk of on-target, off-tumor toxicity in normal tissues. Preclinical findings presented at AACR suggest the potential of ABP-102/CT-P72 to surpass existing HER2-targeted therapies in both efficacy and safety. Key Findings: Highly Selective Tumor Killing: ABP-102/CT-P72 achieves potent cytotoxicity in HER2-overexpressing breast and gastric cancer models while significantly reducing activity against HER2-low cells, addressing a key limitation of prior HER2-targeted T-cell engagers. Enhanced Tumor Growth Inhibition: In vivo studies showed ABP-102/CT-P72 had up to a two-fold increase in tumor suppression compared to a biosimilar of runimotamab, a benchmark HER2 x CD3 bispecific antibody. Reduced Cytokine Release: Engineered for functionally monovalent CD3 binding, ABP-102/CT-P72 minimizes cytokine-related toxicities, as demonstrated by reduced cytokine release in HER2-low cell models while maintaining potent cytotoxicity in HER2-high models. Improved Tolerability: Dose escalation studies in cynomolgus monkeys confirmed that ABP-102/CT-P72 was well tolerated, even at doses exceeding 180 times the maximum tolerated dose observed with the parental antibody, suggesting a broader therapeutic window. The combination of HER2-selective T-cell activation, reduced cytokine release in HER2-low environments, and high tolerability in non-human primates underscores how ABP-102/CT-P72’s functionally monovalent CD3 binding strategy successfully mitigates on-target off-tumor toxicity. These attributes position ABP-102/CT-P72 as a potentially safer alternative to previous HER2-targeting T-cell engagers, paving the way for a broader therapeutic window in clinical trials, which are planned to start in the first half of 2026.공시 • Apr 09Abpro Holdings Receives Written Notice from the Listing Qualifications Department of the Nasdaq Stock MarketOn April 2, 2025, Abpro Holdings, Inc. received written notice from the Listing Qualifications Department of The Nasdaq Stock Market notifying the Company that, based on the closing bid price of the Company’s common stock for the last 30 consecutive business days, the Company no longer complies with the minimum bid price requirement for continued listing on The Nasdaq Stock Market LLC. Nasdaq Listing Rule 5450(a)(1) requires listed securities to maintain a minimum bid price of $1.00 per share (the “Minimum Bid Price Requirement”), and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the Minimum Bid Price Requirement exists if the deficiency continues for a period of 30 consecutive business days. The Notice has no immediate effect on the listing of the Company’s common stock on Nasdaq. Pursuant to the Nasdaq Listing Rules, the Company has been provided an initial compliance period of 180 calendar days to regain compliance with the Minimum Bid Price Requirement. To regain compliance, the closing bid price of the Company’s common stock must be at least $1.00 per share for a minimum of 10 consecutive business days prior to September 29, 2025. If the Company does not regain compliance by September 29, 2025, the Company may be eligible for an additional 180 calendar day compliance period. If the Company does not regain compliance within the compliance period(s), including any extensions that may be granted by Nasdaq, Nasdaq will provide notice that the Company’s common stock will be subject to delisting. The Company intends to monitor the closing bid price of the Company’s common stock and consider its available options to resolve the noncompliance with the Minimum Bid Price Requirement.공시 • Apr 02Abpro Holdings, Inc. announced delayed annual 10-K filingOn 04/01/2025, Abpro Holdings, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.공시 • Mar 09Abpro Holdings, Inc. and Abpro Corporation Announces Termination of Ian Chan as Chief Executive OfficerOn March 7, 2025, Abpro Holdings, Inc. announced that it had terminated Ian Chan as Chief Executive Officer and principal executive officer of the Company, effective as of March 3, 2025. In addition, pursuant to Mr. Chan’s employment agreement with the Company’s wholly-owned subsidiary, Abpro Corporation, Mr. Chan was notified that he was terminated as Chief Executive Officer and director of Abpro Corporation, effective March 3, 2025.공시 • Dec 14Abpro Holdings, Inc. announced that it expects to receive $50 million in funding from Yorkville Advisors LLCAbpro Holdings, Inc. entered into a Standby Equity Purchase Agreement with Yorkville to issue up to $50 million on December 12, 2024.공시 • Nov 29Abpro Holdings, Inc. Announces Resignation of Shahraab Ahmad as Chief Financial OfficerOn November 21, 2024, Shahraab Ahmad notified Abpro Holdings, Inc., a Delaware corporation (the “Company”) of his resignation as the Company’s Chief Financial Officer, effective November 22, 2024.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 ABPO 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: ABPO 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Abpro Holdings 배당 수익률 vs 시장ABPO의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (ABPO)n/a시장 하위 25% (US)1.4%시장 상위 25% (US)4.2%업계 평균 (Biotechs)2.4%분석가 예측 (ABPO) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 ABPO 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 ABPO 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 ABPO 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: ABPO 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/31 20:59종가2026/05/29 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Abpro Holdings, Inc.는 1명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Jason McCarthyMaxim Group
공시 • May 16Abpro Holdings, Inc. announced delayed 10-Q filingOn 05/15/2026, Abpro Holdings, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Apr 01Abpro Holdings, Inc. announced delayed annual 10-K filingOn 03/31/2026, Abpro Holdings, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
공시 • Feb 21Abpro Holdings, Inc. Receives Notice of Nasdaq Delisting and Trading Suspension on February 23, 2026On February 18, 2026, Abpro Holdings, Inc. (the Company") received written notification from the Nasdaq Hearings Panel (the Panel") of the Nasdaq Stock Market LLC (Nasdaq") stating that, due to the Company not having met the terms of the Panel's November 10, 2025 decision that the Company demonstrate compliance with the minimum equity standard requirement under Nasdaq Listing Rule 5550(b)(1) by February 16, 2026, the Company's securities will be delisted from Nasdaq, and trading will be suspended at the open of trading on February 23, 2026. The Company has 15 days after the date it received notice of the Panel's decision to request that the Nasdaq Listing and Hearing Review Council (the Council") review the decision. The Company expects to appeal the Panel's decision. If no appeal is taken, the Company expects Nasdaq will file a Form 25 with the SEC to delist the securities from Nasdaq and deregister the securities under Section 12(b) of the Securities Exchange Act of 1934, as amended. Following suspension of trading on Nasdaq, the Company expects its common stock will be eligible for quotation on the OTC Pink Market under its existing symbol, ABP" and its public warrants under the existing symbol ABPWW." The Company can provide no assurances that any broker-dealer will make a market in its common stock or public warrants or that trading levels, liquidity, or quotation prices will be maintained. The Company also cautions its stockholders and public warrant holders that trading on the OTC Pink Market may be subject to limited availability of information, reduced transparency and liquidity and greater volatility.
공시 • Feb 12Abpro Holdings, Inc. Receives Non-Compliance Notice from NasdaqAs previously disclosed, on January 28, 2026, Anthony D. Eisenberg notified the Board of Directors (the Board") of Abpro Holdings, Inc. (the Company") of his resignation from the Board and all committees thereof. On January 30, 2026, Sooyoung Lee notified the Board of his resignation from the Board and all committees thereof. Following these resignations, the Board has initiated a process to identify and appoint qualified independent directors to fill the resulting vacancies and to satisfy the applicable requirements of The Nasdaq Stock Market (Nasdaq"). On February 5, 2026, the Company received written notice from Nasdaq stating that, as a result of the resignations described above, the Company is no longer in compliance with Nasdaq Listing Rule 5605(b)(1), which requires a majority of the Board to be comprised of independent directors as defined in Nasdaq Listing Rule 5605(a)(2), and Nasdaq Listing Rule 5605(c)(2), which requires the audit committee of the Board (the Audit Committee") to consist of at least three members, each of whom is an independent director under the Nasdaq Listing Rules and meets the heightened independence standards applicable to audit committee members. Furthermore, the Company is not eligible for the cure period provided under Nasdaq Listing Rules 5605(b)(1)(A) and 5605(c)(4) because there is more than one vacancy on the Board and the Audit Committee. Accordingly, the Company's noncompliance with Nasdaq Listing Rules 5605(b)(1)(A) and 5605(c)(4) constitutes additional bases for delisting the Company's securities from Nasdaq. The notice further stated that the Nasdaq Hearings Panel (the Panel") will consider these additional deficiencies in connection with its determination regarding the Company's continued listing on The Nasdaq Capital Market and required the Company to submit its views with respect to these matters to the Panel in writing no later than February 12, 2026. On February 5, 2026, the Company received a separate notice from Nasdaq notifying the Company that as a result of the resignations of Mr. Eisenberg and Mr. Lee, the Company no longer complies with Nasdaq's compensation committee requirements as set in Nasdaq Listing Rule 5605(d)(2)(A), which requires the Company's compensation committee (the Compensation Committee") to consists of at least two members, each of whom is an independent director under the Nasdaq Listing Rules. The notice provides that consistent with Nasdaq Listing Rule 5605(d)(4), the Company has a cure period to regain compliance, which extends until (1) the earlier of the Company's next annual shareholders' meeting or January 30, 2027; or (2) if the next annual shareholders' meeting is held before July 29, 2026, then the Company must evidence compliance no later than July 29, 2026. The Company intends to appoint qualified replacements to fill the vacancies on its Compensation Committee who satisfy the applicable requirements of the Nasdaq Listing Rules prior to the expiration of the applicable cure period. Neither of the Nasdaq notices has an immediate effect on the listing of the Company's common stock or warrants on Nasdaq. However, there can be no assurance that the Panel will grant the Company's request for continued listing or that the Company will be able to regain compliance with the applicable Nasdaq Listing Rules within the required time periods.
공시 • Jan 24Abpro Holdings, Inc. Announces Board and Committee ChangesAbpro Holdings, Inc. announced that on January 16, 2026, Ian McDonald, a member of the Board of Directors (the “Board”) of the Company, notified the Board that he was resigning from the Board, including all committees of the Board. Mr. McDonald did not resign due to any disagreement with the Company, its board of directors or its management regarding any matters relating to the Company’s operations, policies or practices. On January 16, 2026, the Board appointed Dr. Byung-Hak Yoon to fill the vacancy resulting from Mr. McDonald’s resignation. Dr. Yoon will serve as a Class I director with a term ending at the 2028 annual meeting and will fill the vacancies on the Company’s Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee resulting from Mr. McDonald’s resignation. Dr. Yoon, age 51, currently serves as CEO of OQPBIOM, a biotechnology company (since March 2025), and CEO of Doowon Science Pharma (since October 2023). From June 2020 to March 2025, he served as President of CanariaBio Group. From 2022 to 2025, he served as CEO of Sejong Medica, a medical device company. From January 2020 to January 2023, he served as Chairman and CEO of Thelma Therapeutics, and from September 2018 to January 2020, he served as CEO of AXCESO Biopharma. Since January 2018, he has served as a member of the Government Project Review Committee, Ministry of SMEs and Startups, Korea, and as a member of the Government Project Review Committee, Korea Health Industry Development Institute, Korea, since February 2013. Dr. Yoon was appointed to the Board because of his extensive experience in the pharmaceutical industry.
공시 • Jan 07Abpro Holdings, Inc. and Celltrion, Inc. Announce U.S. FDA IND Clearance for Lead Multispecific Antibody Cancer Candidate ABP-102 / CT-P72Abpro Holdings, Inc. announced, together with its co-development partner Celltrion, Inc., that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for ABP-102 /CT-P72, Abpro's lead multispecific antibody oncology program. The IND clearance enables the initiation of a Phase 1 clinical trial evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of ABP-102 /CT-P72 in patients with HER2-positive solid tumors. The Phase 1 clinical study will be led by Celltrion as part of the ongoing joint strategic collaboration to ensure the robust progression of the ABP-102 /CT -P72 program. ABP-102 /CT the company is a multispecific HER2 x CD3 T-cell engager engineered to selectively target HER2-overexpressing tumor cells while engaging cytotoxic T cells, with optimized binding designed to enhance tumor selectivity and limit activity in normal HER2-low tissues. This design is intended to direct immune activity toward cancer cells while seeking to minimize damage to healthy tissue, addressing a key safety challenge that has limited the use of T-cell engagers in solid tumors. In preclinical studies, ABP-102 /CT/CT-P72 demonstrated robust antitumor activity in HER2-high tumor models, including dual xenograft models containing both HER2-high and HER2-low tumors, with selective efficacy for HER2-high tumors. The optimized CD3 binding of ABP-102/CT-P72, functionally linked with HER2-high selectivity, is intended to mitigate excessive immune activation and reduce the risk of cytokine release syndrome. Non-human primate toxicology studies showed the candidate was well tolerated at doses up to 80 mg/kg, with no significant adverse effects observed, supporting a differentiated therapeutic index. Additional preclinical evaluations demonstrated activity in tumor models representing resistance to existing HER2-directed therapies, highlighting the potential to address areas of unmet medical need. Preclinical data sets for ABP-102 /TC-P72 have been presented at major scientific meetings, including the 2025 Annual Meeting of the American Association for Cancer Research and the 2025 Annual Meeting of the Society for Immunotherapy of Cancer. Following IND clearance, Abpro and Celltrion plan to initiate a global Phase 1 clinical trial in the first half of 2026, subject to final site activation and regulatory processes. The study is expected to include dose-escalation and dose-expansion cohorts and will inform future clinical development strategies.
공시 • Dec 16Abpro Holdings, Inc. and Celltrion, Inc. Announces Submission of an IND Application to Initiate a Phase 1 Clinical Trial of T Cell Engager ABP-102/CT-P72 for HER2-Positive CancersAbpro Holdings, Inc. together with its co-development partner Celltrion, Inc. announced the submission of an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for ABP-102/CT-P72, a HER2 x CD3 T cell engager engineered with optimized CD3 and HER2 binding to improve tumor selectivity. Pending regulatory clearance, this IND will support the initiation of a phase 1 clinical trial, anticipated to begin in 1H 2026 in patients with HER2-positive cancers including breast and gastric cancers. This submission represents a significant milestone in the companies' collaborative development of ABP- 102/CT-P72 and marks an important advance for Abpro's broader immuno-oncology pipeline. Upon FDA authorization to proceed, the planned phase 1 study will evaluate the safety, pharmacokinetics, and preliminary efficacy of ABP-102/CT-P72 in a dose-escalation and dose-expansion format. Data generated from the trial will inform dose selection and guide subsequent clinical development.
공시 • Oct 18Nasdaq Schedules Hearing for Abpro Holdings, Inc. Regarding Delisting NoticeAs previously disclosed, Abpro Holdings, Inc. (the Company") requested a hearing (the Hearing") before an independent Hearings Panel (the Panel") regarding a delisting notice in connection with its failure to comply with Nasdaq Listing Rule 5450(a)(1) (the Minimum Bid Price Requirement"). The Hearing has been scheduled for October 30, 2025. As previously disclosed, on April 10, 2025, the Company received two letters from the listing qualifications department staff of The Nasdaq Stock Market (Nasdaq"). One letter (the MVPHS Notice") indicated that based upon Nasdaq's review of the Company's Market Value of Publicly Held Shares (MVPHS") for the last 30 consecutive business days prior to the date of the MVPHS Notice, the Company no longer meets the requirements of Nasdaq Listing Rule 5450(b)(2)(C), which requires listed securities to maintain a minimum MVPHS of $15,000,000 (theMVPHS Requirement"). The second letter notified the Company that from February 20, 2025, to April 9, 2025, the Company's Market Value of Listed Securities (MVLS") was below the minimum of $50 million required for continued listing on The Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(b)(2)(A) (the MVLS Requirement"). Each letter stated that the Company had 180 calendar days, or until October 7, 2025, to regain compliance. On October 14, 2025, the Company received a letter (the Notice") from Nasdaq notifying the Company that it had not regained compliance with either the MVPHS Requirement or the MVLS Requirement during the compliance period. During the Hearing, the Company will present its plans to regain compliance with the Minimum Bid Price Requirement, the MVPHS requirement and the MVLS requirement. Any further delisting action has been stayed pending the Panel's decision and/or any further extension provided by the Panel; therefore, the Notice has no immediate effect on the listing of the Company's common stock or warrants on Nasdaq. There can be no assurance that the Panel will grant the Company's request for continued listing or that the Company will be able to evidence compliance prior to the expiration of any extension that may be granted by the Panel.
공시 • Oct 04Abpro Holdings Receives Notice of Nasdaq Delisting Due to Non-Compliance with Bid Price RuleAs previously reported, on April 2, 2025, Abpro Holdings, Inc. received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that it no longer complied with the minimum bid price requirement for continued listing on Nasdaq. Nasdaq Listing Rule 5450(a)(1) requires listed securities to maintain a minimum bid price of $1.00 per share. The letter stated that the Company had 180 calendar days, or until September 29, 2025, to regain compliance. On September 30, 2025, the Company received a letter from Nasdaq notifying the Company that it had not regained compliance with the Minimum Bid Price Requirement during the compliance period. Accordingly, unless the Company requests an appeal by October 7, 2025, the Company’s common stock will be scheduled for delisting at the opening of business on October 9, 2025. Accordingly, the Company intends to timely request a hearing before the appeal panel. The hearing request will stay the suspension of the Company’s securities with Nasdaq pending the Panel’s decision or any extension of time provided by the Panel to regain compliance. During the hearing, the Company will present its plans to regain compliance with the bid price and all other continued listing requirements. There can be no assurance that the Panel will grant the Company’s request for continued listing or that the Company will be able to evidence compliance prior to the expiration of any extension that may be granted by the Panel.
공시 • May 01Abpro Holdings, Inc., Annual General Meeting, May 20, 2025Abpro Holdings, Inc., Annual General Meeting, May 20, 2025.
공시 • Apr 28Abpro and Celltrion Unveil Preclinical Data for ABP-102/CT-P72 at AACR 2025, Showcasing Potential Best-in-Class HER2 x CD3 T-Cell EngagerAbpro Holdings, Inc. and Celltrion unveiled preclinical data for ABP-102/CT-P72 in an oral presentation at the American Association for Cancer Research® (AACR) Annual Meeting 2025, in the New Drugs on the Horizon session. ABP-102/CT-P72, a tetravalent bispecific HER2 x CD3 T-cell engager co-developed with Celltrion, is engineered to selectively target HER2-overexpressing tumors while reducing the risk of on-target, off-tumor toxicity in normal tissues. Preclinical findings presented at AACR suggest the potential of ABP-102/CT-P72 to surpass existing HER2-targeted therapies in both efficacy and safety. Key Findings: Highly Selective Tumor Killing: ABP-102/CT-P72 achieves potent cytotoxicity in HER2-overexpressing breast and gastric cancer models while significantly reducing activity against HER2-low cells, addressing a key limitation of prior HER2-targeted T-cell engagers. Enhanced Tumor Growth Inhibition: In vivo studies showed ABP-102/CT-P72 had up to a two-fold increase in tumor suppression compared to a biosimilar of runimotamab, a benchmark HER2 x CD3 bispecific antibody. Reduced Cytokine Release: Engineered for functionally monovalent CD3 binding, ABP-102/CT-P72 minimizes cytokine-related toxicities, as demonstrated by reduced cytokine release in HER2-low cell models while maintaining potent cytotoxicity in HER2-high models. Improved Tolerability: Dose escalation studies in cynomolgus monkeys confirmed that ABP-102/CT-P72 was well tolerated, even at doses exceeding 180 times the maximum tolerated dose observed with the parental antibody, suggesting a broader therapeutic window. The combination of HER2-selective T-cell activation, reduced cytokine release in HER2-low environments, and high tolerability in non-human primates underscores how ABP-102/CT-P72’s functionally monovalent CD3 binding strategy successfully mitigates on-target off-tumor toxicity. These attributes position ABP-102/CT-P72 as a potentially safer alternative to previous HER2-targeting T-cell engagers, paving the way for a broader therapeutic window in clinical trials, which are planned to start in the first half of 2026.
공시 • Apr 09Abpro Holdings Receives Written Notice from the Listing Qualifications Department of the Nasdaq Stock MarketOn April 2, 2025, Abpro Holdings, Inc. received written notice from the Listing Qualifications Department of The Nasdaq Stock Market notifying the Company that, based on the closing bid price of the Company’s common stock for the last 30 consecutive business days, the Company no longer complies with the minimum bid price requirement for continued listing on The Nasdaq Stock Market LLC. Nasdaq Listing Rule 5450(a)(1) requires listed securities to maintain a minimum bid price of $1.00 per share (the “Minimum Bid Price Requirement”), and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the Minimum Bid Price Requirement exists if the deficiency continues for a period of 30 consecutive business days. The Notice has no immediate effect on the listing of the Company’s common stock on Nasdaq. Pursuant to the Nasdaq Listing Rules, the Company has been provided an initial compliance period of 180 calendar days to regain compliance with the Minimum Bid Price Requirement. To regain compliance, the closing bid price of the Company’s common stock must be at least $1.00 per share for a minimum of 10 consecutive business days prior to September 29, 2025. If the Company does not regain compliance by September 29, 2025, the Company may be eligible for an additional 180 calendar day compliance period. If the Company does not regain compliance within the compliance period(s), including any extensions that may be granted by Nasdaq, Nasdaq will provide notice that the Company’s common stock will be subject to delisting. The Company intends to monitor the closing bid price of the Company’s common stock and consider its available options to resolve the noncompliance with the Minimum Bid Price Requirement.
공시 • Apr 02Abpro Holdings, Inc. announced delayed annual 10-K filingOn 04/01/2025, Abpro Holdings, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
공시 • Mar 09Abpro Holdings, Inc. and Abpro Corporation Announces Termination of Ian Chan as Chief Executive OfficerOn March 7, 2025, Abpro Holdings, Inc. announced that it had terminated Ian Chan as Chief Executive Officer and principal executive officer of the Company, effective as of March 3, 2025. In addition, pursuant to Mr. Chan’s employment agreement with the Company’s wholly-owned subsidiary, Abpro Corporation, Mr. Chan was notified that he was terminated as Chief Executive Officer and director of Abpro Corporation, effective March 3, 2025.
공시 • Dec 14Abpro Holdings, Inc. announced that it expects to receive $50 million in funding from Yorkville Advisors LLCAbpro Holdings, Inc. entered into a Standby Equity Purchase Agreement with Yorkville to issue up to $50 million on December 12, 2024.
공시 • Nov 29Abpro Holdings, Inc. Announces Resignation of Shahraab Ahmad as Chief Financial OfficerOn November 21, 2024, Shahraab Ahmad notified Abpro Holdings, Inc., a Delaware corporation (the “Company”) of his resignation as the Company’s Chief Financial Officer, effective November 22, 2024.